Investigation Launched by Pomerantz Law Firm on Globus Medical, Inc. Investors' Claims

Investor Alert: Pomerantz Law Firm Investigates Globus Medical, Inc.



Pomerantz LLP has announced that it is currently investigating claims made on behalf of investors of Globus Medical, Inc. (NYSE: GMED), following concerning recent financial disclosures by the company. Investors who have experienced losses are encouraged to reach out to the firm for assistance and potential class action participation.

Circumstances of Investigation



The investigation revolves around allegations that certain officers and directors of Globus Medical may have engaged in securities fraud or other illicit business practices. This scrutiny comes in the wake of the company's first-quarter financial results for 2025, which did not meet investor expectations and caused a significant drop in share price.

On May 8, 2025, Globus Medical reported a non-GAAP earnings per share of $0.68, falling short of consensus estimates by $0.06. Additionally, the company's revenue of $598.12 million missed projections by $27.78 million, which represented a 1.4% year-over-year decline. The disappointing results were attributed to various factors, including a slowdown in Enabling Technology deal closures, temporary supply chain disruptions, and timing issues with international distributor orders.

Following this release, Globus’s stock plummeted by $16.64 per share, translating to a 22.96% decline, closing at $55.82 per share on May 9, 2025. This steep drop has raised concerns among investors about the management’s accountability and the company's market integrity.

Pomerantz LLP's Role



Pomerantz LLP is recognized as a leading firm in the domain of corporate, securities, and antitrust class litigation, established by Abraham L. Pomerantz, a trailblazer in the field of securities class actions. The firm has over 85 years of experience advocating for investors seeking justice against fraudulent practices, breaches of fiduciary duty, and corporate malfeasance. Historically, Pomerantz has secured numerous multi-million dollar settlements for class members whose investments were adversely impacted by corporate misconduct.

Investors interested in more information or wishing to join the class action are urged to contact Danielle Peyton at Pomerantz LLP either through email at [email protected] or by calling 646-581-9980, ext. 7980.

Globus Medical, which specializes in designing and manufacturing innovative surgical solutions for the treatment of spinal disorders, must now navigate its current reputation and shareholder trust in light of these developments. As this situation unfolds, further scrutiny and public interest are likely to escalate, particularly as affected investors seek resolutions for their losses and clarity on the company's operational integrity.

For ongoing updates, prospective class action members are advised to monitor developments from both Pomerantz and Globus Medical. As always, investors should remain vigilant, educated about corporate practices, and proactive in protecting their investment interests.

Topics Financial Services & Investing)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.